Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.92 USD | +1.05% | +7.26% | -38.26% |
05-09 | The Beauty Health Company Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-09 | (SKIN) THE BEAUTY HEALTH COMPANY Forecasts Q2 Revenue Range $96M - $102M | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- For several months, analysts have been revising their EPS estimates roughly upwards.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company has insufficient levels of profitability.
- The group shows a rather high level of debt in proportion to its EBITDA.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Personal Products
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-38.26% | 237M | D+ | ||
-9.01% | 235B | B- | ||
0.00% | 19.58B | - | - | |
+7.90% | 11.4B | A- | ||
-19.32% | 8.65B | A- | ||
+15.38% | 7.45B | B+ | ||
+11.66% | 6.03B | B | ||
-7.99% | 3.87B | B+ | ||
-19.43% | 3.72B | C- | ||
-3.22% | 3.63B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SKIN Stock
- Ratings The Beauty Health Company